Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

536 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
Cefalù AB, D'Erasmo L, Iannuzzo G, Noto D, Giammanco A, Montali A, Zambon A, Forte F, Suppressa P, Giannini S, Barbagallo CM, Ganci A, Nardi E, Vernuccio F, Caldarella R, Ciaccio M, Arca M, Averna M. Cefalù AB, et al. Among authors: zambon a. Atherosclerosis. 2022 Oct;359:13-19. doi: 10.1016/j.atherosclerosis.2022.08.017. Epub 2022 Sep 10. Atherosclerosis. 2022. PMID: 36152419 Free article.
Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes.
D'Erasmo L, Minicocci I, Nicolucci A, Pintus P, Roeters Van Lennep JE, Masana L, Mata P, Sánchez-Hernández RM, Prieto-Matos P, Real JT, Ascaso JF, Lafuente EE, Pocovi M, Fuentes FJ, Muntoni S, Bertolini S, Sirtori C, Calabresi L, Pavanello C, Averna M, Cefalu AB, Noto D, Pacifico AA, Pes GM, Harada-Shiba M, Manzato E, Zambon S, Zambon A, Vogt A, Scardapane M, Sjouke B, Fellin R, Arca M. D'Erasmo L, et al. Among authors: zambon a, zambon s. J Am Coll Cardiol. 2018 Jan 23;71(3):279-288. doi: 10.1016/j.jacc.2017.11.028. J Am Coll Cardiol. 2018. PMID: 29348020 Free article.
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts].
Lettino M, Zambon A, Musumeci G, Arca M, Bilato C, Brunetti ND, Calabrò P, Casu G, Chiarella F, Faggiano P, Ferlini M, Guardigli G, Imbalzano E, Indolfi C, Marcucci R, Menozzi A, Mureddu GF, Filardi PP, Pirro M, Pisciotta L, Scherillo M, Suppressa P, Uguccioni M, Varbella F, Gentile L, Rapezzi C, Averna M. Lettino M, et al. Among authors: zambon a. G Ital Cardiol (Rome). 2020 Apr;21(4 Suppl 1):3S-21S. doi: 10.1714/3331.33006. G Ital Cardiol (Rome). 2020. PMID: 32202541 Italian.
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force.
Averna M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, Magni P, März W, Masana L, Mello E Silva A, Reiner Z, Ros E, Vrablik M, Zambon A, Zamorano JL, Stock JK, Tokgözoğlu LS, Catapano AL. Averna M, et al. Among authors: zambon a. Atherosclerosis. 2021 May;325:99-109. doi: 10.1016/j.atherosclerosis.2021.03.039. Epub 2021 Apr 13. Atherosclerosis. 2021. PMID: 33892925
Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group.
Pederiva C, Capra ME, Biasucci G, Banderali G, Fabrizi E, Gazzotti M, Casula M, Catapano AL; LIPIGEN Paediatric Group; MEMBERS OF THE LIPIGEN STEERING COMMITTEE; Arca M, Averna M, Bertolini S, Calandra S, Catapano AL, Tarugi P; PRINCIPAL INVESTIGATORS; Coordinator center; Pellegatta F; Participant Centers; Participant COLLABORATORS; STUDY COORDINATING GROUP. Pederiva C, et al. Atherosclerosis. 2022 May;349:233-239. doi: 10.1016/j.atherosclerosis.2022.04.021. Epub 2022 Apr 25. Atherosclerosis. 2022. PMID: 35562202
New and Emerging Therapies for Dyslipidemia.
Zambon A, Averna M, D'Erasmo L, Arca M, Catapano A. Zambon A, et al. Endocrinol Metab Clin North Am. 2022 Sep;51(3):635-653. doi: 10.1016/j.ecl.2022.02.004. Epub 2022 Jul 10. Endocrinol Metab Clin North Am. 2022. PMID: 35963633 Review.
A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort.
Cefalù AB, Garbelotto R, Mombelli G, Pirro M, Rubba P, Arca M, Borghi C, Bonomo K, Gonnelli S, Massaroni K, Tirone G, Averna M; ODYSSEY APPRISE Study Italian Investigators. Cefalù AB, et al. Nutr Metab Cardiovasc Dis. 2022 Nov;32(11):2638-2646. doi: 10.1016/j.numecd.2022.07.020. Epub 2022 Aug 9. Nutr Metab Cardiovasc Dis. 2022. PMID: 36064689 Free article. Clinical Trial.
Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
Arca M, Celant S, Olimpieri PP, Colatrella A, Tomassini L, D'Erasmo L, Averna M, Zambon A, Catapano AL, Russo P. Arca M, et al. Among authors: zambon a. J Am Heart Assoc. 2023 Nov 7;12(21):e026550. doi: 10.1161/JAHA.122.026550. Epub 2023 Oct 18. J Am Heart Assoc. 2023. PMID: 37850449 Free PMC article.
536 results